Prediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer

Bašová, Petra; Pešta, Michal; Sochor, Marek; Stopka, Tomáš

doi:10.3390/ijms18102116

Cited by 25 publications

(28 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on previous microarray assay and RT-PCR data (11), miR-155, miR-96 and miR-99a were selected as candidate miRNAs for the diagnosis and prognosis of HCC. miR-155 acts as an oncogenic miRNA, which has been found to be upregulated in various types of tumor, such as breast cancer (15), gastric cancer (16), lung cancer (17), colorectal cancer (18) and other solid malignancies. Bašová et al (15) indicated that there was a positive correlation between miR-155 levels and the pathogenesis of early breast cancer relapse, particularly at the time of post-surgery.…”

Section: Discussionmentioning

confidence: 99%

“…miR-155 acts as an oncogenic miRNA, which has been found to be upregulated in various types of tumor, such as breast cancer (15), gastric cancer (16), lung cancer (17), colorectal cancer (18) and other solid malignancies. Bašová et al (15) indicated that there was a positive correlation between miR-155 levels and the pathogenesis of early breast cancer relapse, particularly at the time of post-surgery. These previous data suggested that oncogenic miRNAs (miR-155 and miR-24) in serum may enable not only the monitoring of early breast cancer, but may also become a highly valuable tool for the detection of relapse in patients with early breast cancer (15).…”

Section: Discussionmentioning

confidence: 99%

“…Bašová et al (15) indicated that there was a positive correlation between miR-155 levels and the pathogenesis of early breast cancer relapse, particularly at the time of post-surgery. These previous data suggested that oncogenic miRNAs (miR-155 and miR-24) in serum may enable not only the monitoring of early breast cancer, but may also become a highly valuable tool for the detection of relapse in patients with early breast cancer (15). The expression levels of miR-155 were significantly increased in gastric cancer tissues, and the upregulation of miR-155 promoted proliferation and migration of gastric cancer cells (16).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

miR‑155, miR‑96 and miR‑99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma

et al. 2019

View full text Add to dashboard Cite

Increasing evidence has demonstrated that circulating microRNAs (miRNAs) can be utilized as potential biomarkers for the diagnosis of cancer, as well as a prognostic tool for the management of the disease. Therefore, the present study aimed to evaluate the predictive ability of miRNA (miR)-155, miR-96 and miR-99a for the diagnosis and prognosis of hepatocellular carcinoma (HCC). Tissues were collected from 30 patients with HCC and their matched adjacent normal liver tissues, as well as from serum samples from 30 patients with HCC and 30 healthy controls. Reverse transcription-quantitative PCR was used to measure the expression levels of miR-155, miR-96 and miR-99a. The expression levels of miR-155 and miR-96 were upregulated in the tissues and serum of patients with HCC, whereas miR-99a expression levels were decreased. Receiver operating characteristics (ROC) curve analysis revealed that circulating miR-155, miR-96, miR-99a and a combination of these three miRNAs could serve as diagnostic biomarkers for HCC with areas under the curve (AUC) of 0.84, 0.824, 0.799 and 0.931, respectively. Serum α-fetoprotein (AFP) was detected using electrochemiluminescence immunoassay analyzer. The addition of AFP with the combination of these three miRNAs offered a higher accuracy of HCC diagnosis (AUC, 0.979; sensitivity, 90.0%; specificity, 100.0%). In addition, elevated expression levels of miR-155 and miR-96 were associated with poor survival time of patients with HCC. The panel of miR-155, miR-96, miR-99a and AFP had a higher sensitivity and specificity for the diagnosis of HCC when compared with a single marker. Furthermore, the present data suggested that miR-155 and miR-96 may be potential prognostic markers for the clinical management of patients with HCC. miR-155, miR-96 and miR-99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

miR‑155, miR‑96 and miR‑99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…As a matter of fact, microRNAs are crucial regulators of tumorigenesis and represent a new frontier in cancer diagnosis and prognosis, as well as in the prediction of therapeutic responsiveness. In this regard, recent evidence has proven the usefulness of miRNAs in disease progression monitoring [ 122 , 123 ]. Examples of miRNAs that were implicated in TEX-mediated functions include, but are not limited to, (i) miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205, and miR-214, all of which were found to be expressed in circulating TEXs isolated from ovarian cancer patients [ 124 ]; and (ii) miR-21 and miR-1246, identified as diagnostic and prognostic markers in exosomes from esophageal squamous cell cancer (ESCC) [ 125 , 126 , 127 ].…”

Section: Discussionmentioning

confidence: 99%

The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation

Alfonsi

Grassi

Signore

et al. 2018

IJMS

View full text Add to dashboard Cite

In recent years many articles have underlined the key role of nanovesicles, i.e., exosomes, as information carriers among biological systems including cancer. Tumor-derived exosomes (TEXs) are key players in the dynamic crosstalk between cancer cells and the microenvironment while promote immune system control evasion. In fact, tumors are undoubtedly capable of silencing the immune response through multiple mechanisms, including the release of exosomes. TEXs have been shown to boost tumor growth and promote progression and metastatic spreading via suppression or stimulation of the immune response towards cancer cells. The advantage of immunotherapeutic treatment alone over combining immuno- and conventional therapy is currently debated. Understanding the role of tumor exosome-cargo is of crucial importance for our full comprehension of neoplastic immonosuppression and for the construction of novel therapies and vaccines based on (nano-) vesicles. Furthermore, to devise new anti-cancer approaches, diverse groups investigated the possibility of engineering TEXs by conditioning cancer cells’ own cargo. In this review, we summarize the state of art of TEX-based immunomodulation with a particular focus on the molecular function of non-coding family genes, microRNAs. Finally, we will report on recent efforts in the study of potential applications of engineered exosomes in cancer immunotherapy.

show abstract

“…And multivariate analysis revealed that miR-24-3p could be an independent prognostic indicator for OS of CRC patients ( 10 ). In breast cancer, miR-24 was identified to be highly predictive of early breast cancer relapse ( 38 ). In nasopharyngeal carcinoma, a survey proved that exosomal miR-24-3p could serve as a prognostic biomarker, due to its involvement in tumor pathogenesis by mediating T-cell inhibition ( 25 ).…”

Section: Therapeutic Relevance Of Mir-24 In Cancermentioning

confidence: 99%

MicroRNA-24 in Cancer: A Double Side Medal With Opposite Properties

et al. 2020

View full text Add to dashboard Cite

MicroRNA-24 (miR-24) has been widely studied in a variety of human cancers, which plays different roles in specific type of cancers. In the present review, we summarized the recent surveys regarding the role of miR-24 in different human cancers. On the one hand, miR-24 was reported to be down-regulated in some types of cancer, indicating its role as a tumor suppressor. On the other hand, it has shown that miR-24 was up-regulated in some other types of cancer, even in the same type of cancer, suggesting the role of miR-24 being as an oncogene. Firstly, miR-24 was dysregualted in human cancers, which is related to the clinical performance of cancer patients. Thus miR-24 could be used as a potential non-invasive diagnostic marker in human cancers. Secondly, miR-24 was associated with the tumor initiation and progression, being as a promoter or inhibitor. Therefore, miR-24 might be an effective prognostic biomarker in different type of cancers. Lastly, the abnormal expression of miR-24 was involved in the chemo- and radio- therapies of cancer patients, indicating the role of miR-24 being as a predictive biomarker to cancer treatment. Totally, miR-24 contributes to tumorigenesis, tumor progression, and tumor therapy, which closely related to clinic. The present review shows that miR-24 plays a double role in human cancers and provides plenty of evidences to apply miR-24 as a potential novel therapeutic target in treating human cancers.

show abstract

Prediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer

Cited by 25 publications

References 21 publications

miR‑155, miR‑96 and miR‑99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma

miR‑155, miR‑96 and miR‑99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma

The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation

MicroRNA-24 in Cancer: A Double Side Medal With Opposite Properties

Contact Info

Product

Resources

About